Post
Dementia Action Week 2024: the future of Alzheimer’s diagnostics
Dementia Action Week 2024, which starts today, shines a spotlight on Alzheimer’s disease, the most common cause of dementia. The approval …
Lula’s progress plan for Brazil: A year on
On 30 May 2023, President Lula da Silva assembled the first South American summit in nearly a decade. In reviving …
Sanofi signs $1.2bn licensing agreement for Novavax’s Covid-19 vaccine
Sanofi has signed a $1.2bn licensing agreement with Novavax to co-commercialise its stand-alone adjuvanted Covid-19 vaccine. Starting in 2025, the drugmaker …
RAPT terminates Phase II trials for lead candidate following clinical hold
RAPT Therapeutics has announced plans to terminate two Phase II trials for its lead candidate, zelnecirnon (RPT193), three months after …
Freeline touts positive data for Gaucher disease therapy
Clinical-stage biotech Freeline Therapeutics has announced new positive data affirming the safety and efficacy of its gene therapy FLT201, for …
WestGene wins FDA nod to study mRNA vaccine to treat certain cancers
The US Food and Drug Administration (FDA) has approved an IND to conduct a clinical trial that evaluates an mRNA …
Oral solid dosage manufacturing companies, equipment and market
Oral solid dosage manufacturing companies, equipment and market: Introduction In an industry where precision and compliance are of paramount importance, selecting …
Shionogi secures licence for Maze’s Pompe disease treatment
Shionogi has concluded an exclusive global licence agreement for Maze Therapeutics’s MZE001, an oral glycogen synthase 1 (GYS1) inhibitor to …
Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension
Formosa Pharmaceuticals has announced an exclusive licensing agreement with Tabuk Pharmaceuticals, granting the latter exclusive rights to commercialise the clobetasol …
Four ways the vaccine rush will define infectious disease trends for CROs in 2024
The global healthcare sector has witnessed both unprecedented challenges and achievements over the past few years, most notably during the …
Attovia secures $105m to advance development of lead programmes
Attovia Therapeutics has secured $105m in an oversubscribed Series B financing round to expedite the development of its lead programmes …
Novo Nordisk enters deal to develop obesity therapy
Novo Nordisk has entered a research partnership with Flagship Pioneering and Metaphore Biotechnologies to jointly develop up to two next-generation …
Marinus parts ways with 20% of its workforce
Marinus Pharmaceuticals has announced that it is sacking approximately 20% of its workforce as a part of the company’s plans …
Novo Holdings-backed Commit launches with $17.2m in seed funding
Commit Biologics has emerged from stealth with €16m ($17.2m) in seed money to develop antibody therapies to treat cancer and …
Acumen doses first patient in Phase II Alzheimer’s disease trial
Acumen Pharmaceuticals has dosed the first patient in ALTITUDE-AD, a Phase II trial designed to evaluate the clinical efficacy and …